The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability - PubMed

4 hours ago

Study evaluates the influence of timing of atogepant administration on effectiveness and tolerability in migraine prevention.
Post-hoc analysis of the STAR study with 81 patients (86% female, mean age 50.8 years) over 12 weeks.
Atogepant significantly reduced monthly migraine days (MMDs) from 16.6 to 9.7 and monthly headache days (MHDs) from 19.8 to 11.9.
60% of patients achieved ≥50% reduction in MMDs; adverse events occurred in 42% of participants.
No significant differences in effectiveness or tolerability between morning (57%) and evening (43%) users.
Evening users had higher baseline MIDAS scores but showed greater reduction, reaching similar final scores as morning users.
Taking atogepant without food was associated with a greater reduction in MHDs compared to with food.
Long-term studies needed to confirm findings on timing and food intake effects.

Hasty Briefsbeta